Stream
Stories
-
Jiangsu HengRui Medicine registers Phase 3 trial of SHR-3167 vs insulin degludec in type 2 diabetes
The study, led by Jiangsu HengRui Medicine Co., Ltd., plans to enroll an estimated 680 participants and plans to start in November 2026. It is a multicenter, randomized, open-label Phase III trial comparing once-weekly SHR-3167 with once-daily insulin degludec over up to 33 weeks.
-
Genmab posts results of Phase 3 epcoritamab trial in relapsed/refractory DLBCL
Results for the EPCORE DLBCL-1 study were first posted on ClinicalTrials.gov on November 3, 2026. The randomized, open-label Phase 3 trial enrolled 483 participants and compared subcutaneous epcoritamab with investigator's choice chemotherapy (R-GemOx or BR) in relapsed/refractory diffuse large B-cell lymphoma.
-
Apnimed posts results of Phase 3 AD109 trial in obstructive sleep apnea
The study, enrolling 660 participants, compared AD109 to placebo over 1 year and was completed with primary data posted on November 3, 2026. It began on August 28, 2023 and reached primary completion on May 7, 2025.
-
Johnson & Johnson Consumer posts results of Phase 3 dental pain study
The study, completed in May 2024, enrolled 447 participants and compared a fixed combination of acetaminophen/naproxen sodium with acetaminophen, naproxen sodium, and placebo for postoperative dental pain. Results were first posted on ClinicalTrials.gov on November 3, 2026.
-
Waters acquires MOBILion Systems, adding advanced ion-mobility to its mass spectrometry portfolio
Waters Corporation announced on November 3, 2026 that it has acquired MOBILion Systems, Inc., a pioneer of SLIM high-resolution ion mobility separation technology. The acquisition broadens Waters' entry into the proteomics market, pairing SLIM's separation power with Waters' XevoTM MRT MS speed and resolution enabling superior bottom-up analysis of complex proteomes versus LC-MS alone.
-
Povorcitinib meets primary endpoint in two phase 3 vitiligo trials
The authors reported that povorcitinib 30 mg daily achieved ≥75% improvement in facial Vitiligo Area Scoring Index at week 52 in both STOP-V1 and STOP-V2, with 18.9% versus 6.8% and 18.9% versus 3.1% respectively. Treatment-emergent adverse events were similar to placebo, with 68.7%/66.7% versus 63.7%/62.7% and no class-specific serious events.
-
FDA releases final guidance on reducing transfusion-transmitted Hepatitis B virus
FDA announces availability of the final guidance titled "Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus" on November 3, 2026. The guidance supersedes several earlier documents and applies to the collection of Whole Blood and blood components, including Source Plasma.
-
FDA releases final guidance on potency assurance for cellular and gene therapy products
The notice, published November 3, 2026, announces the availability of the guidance with docket number FDA-2023-D-4299. It recommends a comprehensive strategy grounded in quality risk management for both investigational and licensed CGT products.
-
BioMarin reports third quarter 2026 financial and operating results
BioMarin said total revenues for the third quarter ended September 30, 2026 rose 32% year-over-year to $1.025 billion, driven by 44% growth in metabolic conditions and 12% growth in skeletal conditions. The company also announced a PDUFA target action date of May 30, 2027 for VOXZOGO in hypochondroplasia and that the EMA validated its submission for VOXZOGO in HCH.
-
BioArctic says Novartis terminates collaboration agreement
BioArctic AB announced that Novartis Pharma AG has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025. The company will retain the full USD 30 million upfront payment and recognize the remaining unrecognized portion as revenue in 2026.
-
Brise Pharmaceuticals announces license agreement with AbbVie to advance migraine therapies
Brise said the agreement, entered in 2024, gives AbbVie global development and commercialization rights for two of Brise's preclinical migraine programs. The aggregated potential transaction value could reach up to US $757 million plus royalties on future sales.
-
Roche receives FDA 510(k) clearance for new cobas eplex respiratory pathogen panel 3
Roche announced the FDA 510(k) clearance of the cobas eplex respiratory pathogen panel 3 (RP3), a flexible syndromic test that detects up to 19 viral and bacterial targets from a single nasopharyngeal swab. The panel offers up to five customizable configurations, requires less than one minute of hands-on time, and delivers results in under two hours.